Archive for the ‘Testing’ Category

Another MSM Hit Piece – Lyme Disease: The ‘Yuppie Virus’ With Dangerous False Diagnoses

https://www.thetimes.com/world/us-world/article/lyme-disease-symptoms-serena-williams-alexis-ohainan-dltvc9pcb

Lyme disease: the ‘yuppie virus’ with dangerous false diagnoses

Half a million Americans say they have it — but a slew of celebrity cases is prompting a post-Covid rethink
Bevan Hurley

The Times

Alexis Ohanian, the co-founder of Reddit and husband of the tennis star Serena Williams, was perplexed.

He was showing no symptoms of Lyme disease, and had not spent much time in the wilderness or northeastern US states where the ticks that carry it are most prevalent. And yet, after a “full battery of health scans”, his doctor had told him that he was infected.

Ohanian, 41, who lives in Florida with Williams and their two children, revealed the diagnosis to his 560,000 followers on Twitter/X last month, saying it had taken him by surprise. He was careful to ensure that his personal experience would not be taken as medical advice. “Please talk to a doctor,” he said.  (See link for article)

________________

**Comment**

First off the bat, let’s be clear: MSM hasn’t done any thinking revolving anything about COVID.

Second – if you understand ‘controllers,’ you know that intervention is eventually needed when enough people start questioning the narrative.  Since people are talking about the fact there is an estimated 500,000 NEW cases of Lyme/MSIDS per year, it’s time for the spin-doctors to get busy.  Too many are questioning things.  Too many are asking to be tested.  Too many are getting fed up with doctors who gas-light them instead of helping them.

Enter MSM – a monolithic entity paid by Big Pharma which will do anything to protect its vested interests, including lie or distort facts.

Once you’ve seen it often enough you become aware of the thinly veiled journalism designed to make you doubt what you see with your own eyes, hear with your own ears, and even personally experience.

The article starts out by regurgitating well known disputed Lyme dogma:

  • can cause fever, chills, headache, fatigue, and muscle and joint aches
  • between 5-10% descend into PTLDS and get arthritis, chronic pain, heart palpitations, and brain inflammation

Let’s stop here and state emphatically that Lyme/MSIDS can and does kill people.  Let’s also state emphatically that this complex illness can destroy your life, income, family, and all you hold dear.

OK, now that we got that out of the way…..the article then states that ‘celebrity tell-alls and rampant pseudoscience’ is fueling misdiagnoses.

What about the thousands upon thousands that have been misdiagnosed for decades with virtually everything under the sun when they were infected with Lyme/MSIDS and immediate treatment could have made a real or THE difference?

The usual perps are presented for this angle: mainly representation from the American Lyme Disease Foundation (ALDF), who are known Lyme denialists.  This representative states practitioners are ‘unqualified’ because they have no infectious disease experience and are ‘cashing in’ by selling unreliable blood testing products and treatment.

This refrain is as old as time and is shear propaganda by controllers who want you to believe that only the government can protect consumers by monopolizing testing and treatment.  Well, they have done just that for over 40 years.  Let me ask you, ‘how’s that going?’  Nowhere, that’s where.

Particularly attacked were vitamin supplements and ozone therapy – two of the safest, most effective general treatments that help virtually everything!  But since the FDA can’t do any under the table deals with Big Pharma and make money off them, they are verboten!   

The article also hones in on ‘false positives,’ with Lyme but doesn’t utter a peep over the vast false positives with COVID, along with counting all deaths as COVID, that were purposely used to create a the illusion of vast cases and deaths.

Current Lyme testing is so flawed that a statistical analysis by Cook and Puri found that the LD two-tiered testing resulted in 500 times more false-negative outcomes than similar two-tiered tests used in the diagnosis of AIDS.  

The article also pushes the highly politicized climate change agenda when there is great controversy on many issues within this highly controlled paradigm, and independent research has shown it has nothing to do with tick proliferation or transmission.

While the article is at least honest enough to recognize that countries with nationalized health care struggle even more because there’s ‘there’s no system for them to go outside of,’ and that at least in the U.S. you can still find a doctor who is independent and can think for himself/herself.  But, how long will this last?

According to the author, the oft repeated belief that more funding to the same institutions that have denied Lyme/MSIDS from the get-go is somehow the answer, despite all evidence to the contrary.

Article grade: D

Policy Shifts Against the mRNA Platform Rapidly Emerged This Past Week

https://pierrekorymedicalmusings.com/p/policy-shifts-against-the-mrna-platform?

Policy Shifts Against The mRNA Platform Rapidly Emerged This Past Week

Major Covid mRNA policy reversals and awakenings occurred this week within a major U.S health system, a large U.S state, a South American country, and in the UK. The dominoes are starting to fall.

This week a nurse reached out with disturbing descriptions of some major changes she has witnessed inside the Ohio State University Medical Center (OSUMC) system.

OSUMC s a large and comprehensive healthcare organization, with a significant presence in Ohio and a strong focus on research, education, and patient care. It is a massive institution with over 23,000 employees, including:

  • Over 2,000 physicians
  • More than 1,000 residents and fellows
  • Nearly 5,000 nurses

Lets start off with this screenshot of a webpage from OSUMC’s website which provides information to the public as to where they can get Covid-19 vaccines. Check out the highlighted sentence at the bottom of the page.  (See link for article)

_______________

SUMMARY:

  • OSUMC is suddenly and quietly NOT offering the clot shot to employees, but they are happy to offer them to the public.
  • Please see and read the story perfectly exemplifying medical blindness. This poor woman with an immune disorder went temporarily blind in both eyes, had a locked jaw, and began vomiting after being forced to get THREE vaccines in order to get medical care.

Personally, I was forced to get a completely worthless PCR test before I could have cancer surgery.  Because of testing fraud I had to drive over 2 hours get at least be able to spit in a cup rather than have a dangerous, heavy metal, graphene and glass saturated swab stuck up my nose.  This is a crime.  Both, that this test is still being used and that everyone was required to take it in order to get medical care.  

Nobody talks about how a public ‘health’ agency monopolizes testing which puts far too much power in the hands of a few.

When will this medial madness end?  When will people be allowed to have medical freedom?  When will authorities admit vaccines can be deadly?

Researchers Say New Lyme Test Can Detect Lyme Within 14 Days of Infection

https://www.lymedisease.org/detecting-lyme-within-14-days/

Researchers say this test can detect Lyme within 14 days of infection

Focus on Lyme and Aces Diagnostics Inc. has announced a breakthrough in Lyme disease diagnosis with a new test that detects the disease at all stages, including the crucial first 14 days post-infection, with over 90% accuracy.

Aces Diagnostics is developing and manufacturing this test, aiming for FDA clearance to make it accessible to all patients.

LymeSeek™, developed through a collaboration between Tulane University and Focus on Lyme, combines advanced biomarker research from Tulane’s Monica Embers and nine years of intensive work funded by Focus on Lyme. Enhanced by machine learning, this innovative diagnostic promises to reshape Lyme disease detection.

“Previous tests have been less than 50% accurate, especially in the early stages,” said Tammy Crawford, CEO of Aces Diagnostics. “This has led to countless patients being misdiagnosed or undiagnosed, resulting in prolonged suffering. LymeSeek will change that, providing a reliable diagnostic tool that can save lives.”

Aces Diagnostics Team

The CDC reports that nearly 500,000 people in the U.S. are diagnosed with Lyme disease each year. Globally, 14.5% of the population is affected, with many suffering from chronic symptoms due to delayed diagnosis. A Johns Hopkins study revealed that 38% of Lyme patients continue to experience symptoms six months post-diagnosis, underscoring the need for improved testing.

Simplifying diagnosis

“Current Lyme testing involves multiple steps, with results taking over a week and requiring subjective interpretation,” said Aces Diagnostics Co-Founder Holly Ahern.

“LymeSeek™ will replace this cumbersome process, enabling earlier diagnosis and reducing chronic illness caused by delayed or missed diagnoses.”

Crawford and Ahern are personally invested in this mission, both having daughters who battled Lyme disease. “An early diagnosis could have spared them years of suffering,” said Crawford.

Aces Diagnostics Inc. brings together a team with over 50 years of combined experience in Lyme disease research, backed by a distinguished advisory board that includes experts from Johns Hopkins UniversityColumbia University, and Tulane University. The company is already advancing development and manufacturing efforts and pursuing early FDA clearance to make LymeSeek™ available to the public by the third quarter of 2026.

SOURCE: Focus on Lyme

______________

**Comment**

Testing has been and continues to be a major problem with Lyme/MSIDS for numerous reasons, one of the biggest being the fact many are coinfected with numerous pathogens that mainstream medicine and research never discuss.  These coinfected patients are some of the sickest but are kicked to the curb because testing doesn’t reveal what’s inside them.

While this new test is a step in the right direction, it still doesn’t address those who have been infected for decades or those who are coinfected.  It’s like comparing apples to oranges and until these issues are addressed, it remains a foreign language to mainstream medicine.

The Johns Hopkins study showing nearly 40% go on to suffer symptoms 6 months post-diagnosis is still low in my opinion due to the fact so many are never diagnosed in the first place and so many are infected with multiple things that are never picked up on testing.

But, one must remain hopeful……

For more:

Scrutinizing Clinical Biomarkers in a Large Cohort of Patients with Lyme Disease and Other Tick-Borne Infections

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893018/

 2024 Feb; 12(2): 380.
Published online 2024 Feb 12. doi: 10.3390/microorganisms12020380
PMCID: PMC10893018
PMID: 38399784

Scrutinizing Clinical Biomarkers in a Large Cohort of Patients with Lyme Disease and Other Tick-Borne Infections

David XiConceptualizationMethodologySoftwareFormal analysisInvestigationData curationWriting – original draftWriting – review & editingVisualization,1 Kunal GargConceptualizationMethodologySoftwareFormal analysisInvestigationData curationWriting – review & editingVisualization,2 John S. Lambert,1,3,4 Minha Rajput-RayConceptualizationFormal analysisInvestigationResourcesWriting – review & editingSupervision,5 Anne MadiganConceptualizationFormal analysisInvestigationResourcesData curation,1 Gordana AvramovicConceptualizationMethodologyFormal analysisInvestigationResourcesData curationWriting – review & editingSupervisionProject administration,1 and Leona GilbertConceptualizationMethodologyFormal analysisInvestigationResourcesData curationWriting – original draftWriting – review & editingVisualizationSupervisionProject administration2,*

Abstract

Standard clinical markers can improve tick-borne infection (TBI) diagnoses. We investigated immune and other clinical biomarkers in 110 patients clinically diagnosed with TBIs before (T0) and after antibiotic treatment (T2). At T0, both the initial observation group and patients without seroconversion for tick-borne pathogens exhibited notably low percentages and counts of CD3 percentage (CD3%), CD3+ cells, CD8+ suppressors, CD4 percentage (CD4%), and CD4+ helper cells, with the latter group showing reductions in CD3%, CD3+, and CD8+ counts in approximately 15-22% of cases. Following treatment at the T2 follow-up, patients typically experienced enhancements in their previously low CD3%, CD3+ counts, CD4%, and CD4+ counts; however, there was no notable progress in their low CD8+ counts, and a higher number of patients presented with insufficient transferrin levels. Moreover, among those with negative serology for tick-borne infections, there was an improvement in low CD3% and CD3+ counts, which was more pronounced in patients with deficient transferrin amounts. Among those with CD57+ (n = 37) and CD19+ (n = 101) lymphocyte analysis, 59.46% of patients had a low CD57+ count, 14.85% had a low CD19 count, and 36.63% had a low CD19 percentage (CD19%). Similar findings were observed concerning low CD57+, CD19+, and CD19% markers for negative TBI serology patients. Overall, this study demonstrates that routine standard clinical markers could assist in a TBI diagnosis.

For more:

IGeneX Lyme ImmunoBlot Test Receives FDA Clearance

https://www.lymedisease.org/lyme-immunoblot-fda-clearance/

IGeneX Lyme ImmunoBlot test receives FDA clearance

The Lyme ImmunoBlot test first introduced by IGeneX in 2017 has now been converted to a test kit–and has received FDA clearance.

The name of the test is iDart™ Lyme IgG ImmunoBlot Kit.

It’s a stand-alone test for the detection of IgG antibodies against Borrelia-causing Lyme disease.

The iDart ImmunoBlot Kit features 31 Lyme antigen bands, which are more antigen bands than any other Lyme immunoblot test on the market.

Moreover, it is the only immunoblot that includes Osp A (P31) and Osp B (P34). (Note: those are the two bands removed from other Lyme tests in the 1990s because of their use in the development of Lyme vaccines.)

The inclusion of 31 antigens improves the sensitivity of the detection of Lyme-specific IgG antibodies, which in turn will improve the sensitivity of the diagnosis of Lyme disease in suspected patients without sacrificing specificity.

“We are delighted to have received FDA clearance for our Lyme ImmunoBlot Kit,” said Dr. Jyotsna Shah, Ph.D., President and Director of IGeneX Labs.

These kits are not available for sale to consumers, but only to labs who perform Lyme diagnostic testing.

Key features of the iDart Lyme IgG ImmunoBlot kit

  • Results interpretation is based upon new criteria and not CDC criteria.
  • The bands are grouped according to their antigen groups. The test is considered positive if the Lyme Screen Antigen (LSA) band and one or more bands from at least two other groups are present on the ImmunoBlot.
  • Bands 31 and 34 are included, making this the only FDA-cleared Lyme serological test that includes these bands.

SOURCE: IGeneX, Inc.